BlueWind Medical announced that it closed a financing worth $47.8 million in a combination of equity and debt.

Salt Lake City-based BlueWind plans to use the proceeds to fund further commercialization for its Revi neuromodulation system. Revi, an implantable tibial neuromodulation (ITNM) platform, treats urgency urinary incontinence (UUI). The Revi wearable device delivers neurmodulation therapy to seamlessly support long-term symptom relief.

Related: Rivermark secures $20M in Series D for late-stage prostate device trial

BlueWind won FDA clearance for an enhanced version of Revi at the end of 2025.

Revi is implanted near the ankle during a single outpatient procedure. Patients initiate Revi therapy at their convenience by placing a lightweight, wireless wearable around their ankle once daily. This provides stimulation to the posterior tibial nerve, offering relief from UUI.

BlueWind labeled Revi the first and only FDA-cleared iTNM system activated by an external wireless wearable for patients with UUI. Medtronic joined the market with FDA approval of its Altaviva tibial neuromodulation system for UUI in September 2025. Altaviva activation occurs before a patient goes home, with no daily intervention or manual adjustments required.

According to BlueWind, proceeds should support expansion of its sales organization and ongoing investment in market access initiatives. The company hopes to broaden patient and provider access to the therapy.

Kerry Nelson, CEO of BlueWind Medical, said:

“Urgency urinary incontinence affects millions of people, creating a significant need for effective, durable treatment options that fit seamlessly into patients’ lives. This financing reflects deep conviction in our team, our technology, and the opportunity ahead to establish Revi as the new standard of care.”

Stephen Armstrong, CFO of BlueWind Medical, said:

“This financing is an important milestone for BlueWind and a strong validation of the progress we are making as a leader in implantable tibial neuromodulation for urgency urinary incontinence. The capital allows us to scale our commercial organization, expand market access, and ensure that more patients and providers can benefit from a clinically proven, patient-centric therapy. We are grateful for the continued confidence of our investors as we execute on the next phase of our growth.”